Find financial assistance programs to support your patients. The Rituxan Immunology Co-pay Card Program helps eligible commercially insured patients with their drug co-pays for Rituxan. Eligible commercially insured patients can receive up to $15,000 in assistance per 12-month period. They pay $5 per drug co-pay* until the $15,000 limit is reached.
Full Answer
How do you feel after Rituxan?
After a Rituxan (rituximab) infusion you may experience certain side effects or adverse reactions that make you feel unwell. Rituxan affects different people in different ways, but the more common side effects include: Fever (high temperature), muscle aches, headaches and chills, which are signs of infection.
Is Rituxan a Part B drug?
That made Rituxan – approved to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis – one of six drugs to exceed $1 billion in spending by Medicare part B for the year.
What is Genentech Patient Foundation?
The Genentech Patient Foundation gives free Genentech medicine to people who don't have insurance coverage or who have financial concerns and meet eligibility criteria.
What company makes rituximab?
Rituxan (Rituximab) is a monoclonal antibody indicated for treating advanced follicular lymphoma. The drug was developed by Biogen Idec and is co-promoted by Genentech, a subsidiary of Roche Group.
Does Medicare require a prior authorization for Rituxan?
Prior authorization is required for all treatment with necessary Rituximab (Rituxan®, Truxima®, RiabniTM, RuxienceTM) requested for members enrolled in Harvard Pilgrim StrideSM (HMO) Medicare Advantage.
Where can I get Rituxan?
Authorized Distributors and Specialty PharmaciesDistributorTelephoneFaxCardinal Health Specialty Distribution877-453-3972614-652-7043CenterWell Specialty Pharmacy800-486-2668877-405-7940CuraScript SD877-599-7748800-862-6208McKesson Specialty Health800-482-6700 855-477-9700 (Non-Oncology Customers)800-289-92853 more rows
What drugs does Genentech make?
Our Medicines & ProductsMedicines.Actemra® (TOCILIZUMAB [authorized for Emergency Use])Actemra® (tocilizumab)Activase® (alteplase)Alecensa® (alectinib)Avastin® (bevacizumab)Boniva Tablets® (ibandronate sodium)Cathflo Activase® (alteplase)More items...
Who makes Valganciclovir?
Genentech: Valcyte® (valganciclovir hydrochloride) - Information for Patients.
What is the success rate of rituximab?
Rituximab with bendamustine (Treanda, Cephalon) was studied in a phase 2 trial in patients with relapsed disease. This combination was found to be very effective, with an ORR of 92%.
Will I lose my hair with rituximab?
You could lose all your hair. This includes your eyelashes, eyebrows, underarm, leg and sometimes pubic hair. Your hair will usually grow back once treatment has finished but it is likely to be softer. It may grow back a different colour or be curlier than before.
Why am I so tired after Rituxan?
Serious side effects that can occur with Rituxan include: tumor lysis syndrome (nausea, vomiting, diarrhea, and tiredness that happen due to tumor cells breaking down and releasing their contents into your blood)
What class of drug is Rituxan?
Rituximab injection (Rituxan) is used to treat pemphigus vulgaris (a condition that causes painful blisters on the skin and the lining the mouth, nose, throat and genitals). Rituximab injection products are in a class of medications called monoclonal antibodies.
What type of medicine is rituximab?
Rituximab injection is a monoclonal antibody. Rituximab injection is used together with other medicines (eg, fludarabine cyclophosphamide) to treat chronic lymphocytic leukemia (CLL). Rituximab injection is used together with methotrexate to treat the symptoms of rheumatoid arthritis.
What is the generic name for Rituxan?
Rituxan is the trade name for rituximab. In some cases, health care professionals may use the trade name rituxan when referring to the generic drug name rituximab. Drug type: Rituximab is a monoclonal antibody. (For more detail, see "How this drug works" section below).
How long can you stay on Rituxan?
Rituxan can provide up to 6 months of symptom improvement from 1 course of treatment (2 infusions given 2 weeks apart). Be sure to talk with your doctor to find out if starting and continuing treatment with Rituxan is right for you.
What to tell your healthcare provider before taking Rituximab?
Before receiving RITUXAN, tell your healthcare provider if you: Have had a severe reaction to RITUXAN or a rituximab product. Have a history of heart problems, irregular heartbeat, or chest pain. Have lung or kidney problems. Have had an infection, currently have an infection, or have a weakened immune system.
Where to report RITUXAN side effects?
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555.
How long after a last dose of Rituxan can you give birth?
Females who are able to become pregnant should use effective birth control (contraception) during treatment with RITUXAN and for 12 months after the last dose of RITUXAN.
What to do before a Rituxan infusion?
Your healthcare provider should give you medicines before your infusion of RITUXAN to decrease your chance of having a severe infusion-related reactions. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an infusion of RITUXAN: Hives (red itchy welts) or rash.
How long after a Rituxan can you breastfeed?
Are breastfeeding or plan to breastfeed. It is not known if RITUXAN passes into your breast milk. Do not breastfeed during treatment and for at least 6 months after your last dose of RITUXAN. Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How long after a Rituxan infusion do you have a reaction?
Serious infusion-related reactions can happen during your infusion or within 24 hours after your infusion of RITUXAN.
What does it feel like to have a rituxan?
Severe Skin and Mouth Reactions: Tell your healthcare provider or get medical help right away if you get any of these symptoms at any time during your treatment with RITUXAN: Painful sores or ulcers on your skin, lips, or in your mouth. Blisters.
How long after Rituxan infusion can you have a reaction?
Infusion-Related Reactions: Infusion-related reactions are very common side effects of Rituxan treatment. Serious infusion-related reactions can happen during your infusion or within 24 hours after your infusion of Rituxan. Your healthcare provider should give you medicines before your infusion of Rituxan to decrease your chance of having a severe infusion-related reaction.
How to report side effects of Genentech?
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at (800) FDA‐1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835‐2555.
Can you test if you are pregnant before taking Rituxan?
Your healthcare provider should do a pregnancy test to see if you are pregnant before starting Rituxan.
Does Rituxan cause heart problems?
Heart Problems: Rituxan may cause chest pain, irregular heartbeats, and heart attack. Your healthcare provider may monitor your heart during and after treatment with Rituxan if you have symptoms of heart problems or have a history of heart problems. Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with Rituxan
How many patients tested positive for anti-rituximab?
A total of 273/2578 (11%) patients with RA tested positive for anti-rituximab antibodies at any time after receiving Rituxan. Anti-rituximab antibody positivity was not associated with increased infusion-related reactions or other adverse reactions. Upon further treatment, the proportions of patients with infusion-related reactions were similar between anti-rituximab antibody positive and negative patients, and most reactions were mild to moderate. Four anti-rituximab antibody positive patients had serious infusion-related reactions, and the temporal relationship between anti-rituximab antibody positivity and infusion-related reaction was variable. The clinical relevance of anti-rituximab antibody formation in Rituxan-treated patients is unclear.
What is the rate of serious infections with Rituxan?
In the experience with Rituxan in 2578 RA patients, the rate of serious infection was 4.31 per 100 patient-years. The most common serious infections (≥0.5%) were pneumonia or lower respiratory tract infections, cellulitis, and urinary tract infections. Fatal serious infections included pneumonia, sepsis, and colitis. Rates of serious infection remain stable in patients receiving subsequent courses.
How long after Rituxan infusion do you have an adverse reaction?
Infusion-Related Reactions: In the Rituxan RA pooled, placebo-controlled studies, incidence of any adverse event within 24 hours of an infusion was 32% vs 23% after the first infusion, and 11% vs 13% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Incidence of acute infusion-related reactions was 27% vs 19% after the first infusion, 9% vs 11% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Serious acute infusion-related reactions were experienced by <1% of patients in either treatment group. Acute infusion-related reactions required dose modification (stopping, slowing, or interruption of the infusion) in 10% and 2% of patients receiving Rituxan or placebo, respectively, after the first course.
What is the most common infection with Rituxan?
The most common serious infection was pneumonia. Hypogammaglobulinemia: Hypogammaglobulinemia (IgA, IgG, or IgM below the lower limit of normal) has been observed in patients with GPA and MPA treated with Rituxan in GPA/MPA Study 1.
How long does it take for a patient to reactivate HBV?
HBV reactivation has been reported up to 24 months following completion of Rituxan therapy.
How long before a course of Rituxan can you administer non live shots?
For patients treated with Rituxan, physicians should review the patient’s vaccination status and patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Rituxan and administer non-live vaccines at least 4 weeks prior to a course of Rituxan.
How long does it take for a PV to test positive for Rituximab?
Using a new ELISA assay, a total of 19/34 (56%) patients with PV treated with the Ritux 3 regimen tested positive for anti-rituximab antibodies by 18 months. The clinical relevance of anti-rituximab antibody formation in Rituxan treated PV patients is unclear.
How many patients tested positive for anti-rituximab?
A total of 273/2578 (11%) patients with RA tested positive for anti-rituximab antibodies at any time after receiving Rituxan. Anti-rituximab antibody positivity was not associated with increased infusion-related reactions or other adverse reactions. Upon further treatment, the proportions of patients with infusion-related reactions were similar between anti-rituximab antibody positive and negative patients, and most reactions were mild to moderate. Four anti-rituximab antibody positive patients had serious infusion-related reactions, and the temporal relationship between anti-rituximab antibody positivity and infusion-related reaction was variable. The clinical relevance of anti-rituximab antibody formation in Rituxan-treated patients is unclear.
What is the rate of serious infections with Rituxan?
In the experience with Rituxan in 2578 RA patients, the rate of serious infection was 4.31 per 100 patient-years. The most common serious infections (≥0.5%) were pneumonia or lower respiratory tract infections, cellulitis, and urinary tract infections. Fatal serious infections included pneumonia, sepsis, and colitis. Rates of serious infection remain stable in patients receiving subsequent courses.
How long after Rituxan infusion do you have an adverse reaction?
Infusion-Related Reactions: In the Rituxan RA pooled, placebo-controlled studies, incidence of any adverse event within 24 hours of an infusion was 32% vs 23% after the first infusion, and 11% vs 13% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Incidence of acute infusion-related reactions was 27% vs 19% after the first infusion, 9% vs 11% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Serious acute infusion-related reactions were experienced by <1% of patients in either treatment group. Acute infusion-related reactions required dose modification (stopping, slowing, or interruption of the infusion) in 10% and 2% of patients receiving Rituxan or placebo, respectively, after the first course.
How long does it take for a patient to reactivate HBV?
HBV reactivation has been reported up to 24 months following completion of Rituxan therapy.
How long before a course of Rituxan can you administer non live shots?
For patients treated with Rituxan, physicians should review the patient’s vaccination status and patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Rituxan and administer non-live vaccines at least 4 weeks prior to a course of Rituxan.
How long does it take for a PV to test positive for Rituximab?
Using a new ELISA assay, a total of 19/34 (56%) patients with PV treated with the Ritux 3 regimen tested positive for anti-rituximab antibodies by 18 months. The clinical relevance of anti-rituximab antibody formation in Rituxan treated PV patients is unclear.
What is the most common infection in Rituxan?
The incidence of serious infections was 11% vs 10% (Rituxan-treated vs cyclophosphamide, respectively), with rates of approximately 25 and 28 per 100 patient-years, respectively. The most common serious infection was pneumonia.
Can you breastfeed after rituximab?
There are no data on the presence of rituximab in human milk, the effect on the breastfed child, or the effect on milk production. Since many drugs including antibodies are present in human milk, advise a lactating woman not to breastfeed during treatment and for at least 6 months after the last dose of TRUXIMA due to the potential for serious adverse reactions in breastfed infants
Can rituximab cause fatal reactions?
Infusion-Related Reactions: Administration of rituximab products, including TRUXIMA, can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue TRUXIMA infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions
Can rituximab cause cardiac shock?
Cardiac adverse reactions, including ventricular fibrillation, myocardial infarction, and cardiogenic shock may occur in patients receiving rituximab products. Discontinue infusions for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of TRUXIMA for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina
Can rituximab cause lichenoid dermatitis?
Muco cutaneous reactions, some with fatal outcome, can occur in patients treated with rituximab products. These reactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of these reactions has been variable and includes reports with onset on the first day of rituximab exposure. Discontinue TRUXIMA in patients who experience a severe mucocutaneous reaction. The safety of re-administration of rituximab products to patients with severe mucocutaneous reactions has not been determined
Can rituximab cause renal failure?
Severe, including fatal, renal toxicity can occur after rituximab product administration in patients with NHL. Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. The combination of cisplatin and TRUXIMA is not an approved treatment regimen. Monitor closely for signs of renal failure and discontinue TRUXIMA in patients with a rising serum creatinine or oliguria
